EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Bruce E. Sands  ¹     William Sandborn  ²     Laurent Peyrin-Biroulet  ³     Peter Higgins  ⁴     Fumihito Hirai  ⁵     Vipul Jairath  ⁶     Geert R. D'Haens  ⁷     Maria T. Abreu  ⁸     Ruth Belin  ⁹     Elisa Gomez Valderas  ⁹     Debra Miller  ⁹     April Naegeli  ⁹     Vipin Arora  ⁹     Paul Pollack  ⁹     Jay Tuttle  ⁹     Toshifumi Hibi  ^10    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² University of California San Diego, La Jolla, United States
³ Nancy University Hospital Inserm U 954, Vandoeuvre les Nancy, France
⁴ University of Michigan, Ann Arbor, United States
⁵ Fukuoka University Chikushi Hospital, Chikushino, Japan
⁶ Western University, London, Canada
⁷ University of Amsterdam Academic Medical Center, Amsterdam, Netherlands
⁸ University of Miami, Miller School of Medicine, Miami, United States
⁹ Eli Lilly and Company, Indianapolis, United States
¹⁰ Kitasato Institute Hospital IBD Research and Treatment, Tokyo, Japan

Topic
IBD

Session
IBD: Clinical trials II

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)